Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany.
Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.
Theranostics. 2020 Jun 25;10(17):7921-7924. doi: 10.7150/thno.49577. eCollection 2020.
Following its discovery more than 30 years ago, the enhanced permeability and retention (EPR) effect has become the guiding principle for cancer nanomedicine development. Over the years, the tumor-targeted drug delivery field has made significant progress, as evidenced by the approval of several nanomedicinal anticancer drugs. Recently, however, the existence and the extent of the EPR effect - particularly in patients - have become the focus of intense debate. This is partially due to the disbalance between the huge number of preclinical cancer nanomedicine papers and relatively small number of cancer nanomedicine drug products reaching the market. To move the field forward, we have to improve our understanding of the EPR effect, of its cancer type-specific pathophysiology, of nanomedicine interactions with the heterogeneous tumor microenvironment, of nanomedicine behavior in the body, and of translational aspects that specifically complicate nanomedicinal drug development. In this virtual special issue, 24 research articles and reviews discussing different aspects of the EPR effect and cancer nanomedicine are collected, together providing a comprehensive and complete overview of the current state-of-the-art and future directions in tumor-targeted drug delivery.
三十多年前发现增强型通透性和保留（EPR）效应以来，该效应已成为癌症纳米医学发展的指导原则。多年来，肿瘤靶向药物输送领域取得了重大进展，这体现在批准了几种纳米抗癌药物上。然而，最近 EPR 效应的存在和程度——尤其是在患者中——成为了激烈争论的焦点。这部分是由于临床前癌症纳米医学论文数量众多，而进入市场的癌症纳米医学药物产品相对较少，两者之间存在不平衡。为了推动该领域的发展，我们必须深入了解 EPR 效应、其癌症类型特异性病理生理学、纳米药物与异质肿瘤微环境的相互作用、纳米药物在体内的行为以及特别使纳米药物开发复杂化的转化方面。在这个虚拟特刊中，收集了 24 篇研究文章和综述，讨论了 EPR 效应和癌症纳米医学的不同方面，共同提供了肿瘤靶向药物输送的最新技术和未来方向的全面综合概述。
